comparemela.com

Latest Breaking News On - German institute for quality - Page 1 : comparemela.com

Aflibercept in AMD: no proof of added benefit

Manufacturer's dossier did not contain any usable data for the comparison with ranibizumab The drug aflibercept (trade name: Eylea) has been approved in Germany since November 2012 for the treatment of wet age-related macular degeneration (AMD). In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG)…

Automobili Lamborghini closes the first nine months of 2023 with an operating result exceeding the fiscal year 2022

Automobili Lamborghini closes the first nine months of 2023 with an operating result exceeding the fiscal year 2022
webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.

Zanubrutinib in chronic lymphocytic leukemia:

Zanubrutinib, a second-generation Bruton tyrosine kinase (BTK) inhibitor, is approved for several therapeutic indications. The German Institute for Quality and Efficiency in Health Care (IQWiG) investigated whether the drug has an added benefit compared with the appropriate comparator therapy for adult patients with chronic lymphocytic leukaemia (CLL) after a relapse or in the case of refractory disease, i. e. disease that has not responded to the previous treatment.

Trastuzumab Deruxtecan Shows Benefits in HER2-Low Breast Cancer

Trastuzumab Deruxtecan Shows Benefits in HER2-Low Breast Cancer
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Automobili Lamborghini closes the first nine months of 2023 with an operating result exceeding the fiscal year 2022

Automobili Lamborghini closes the first nine months of 2023 with an operating result exceeding the fiscal year 2022
thenewsmarket.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thenewsmarket.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.